血清血管内皮生长因子及可溶性血管内皮生长因子受体1在系统性红斑狼疮患者中的表达及其意义

目的 研究血清中血管内皮生长因子(VEGF)及可溶性血管内皮生长因子受体1(sFlt-1)在活动期系统性红斑狼疮(SLE)及不同肾脏病理类型的狼疮肾炎(LN)患者中表达的意义. 方法 采用双抗体夹心酶联免疫吸附法(ELISA)对60例SLE患者及30名健康人血清中VEGF及sFlt-1的水平同时进行检测,结合临床资料及肾脏病理进行相关分析. 结果 活动期SLE患者血清VEGF及sFlt-1水平均明显升高;血清中VEGF/sFlt-1的比值健康对照组较活动期SLE、非活动期SLE及LN组患者降低(P＜0.01),Ⅴ型LN组该比值较Ⅱ、Ⅲ、Ⅳ型LN组升高(P＜0.05);血清sFlt-1的浓度与尿蛋白呈正相关(rs=0.6244,P＜0.01),血清VEGF的浓度与尿蛋白无明显相关(rs=0.1807,P＞0.05);血清sFlt-1的浓度与ESR正相关(rs=0.4235,P＜0.01),血清VEGF的浓度与ESR无明显相关(rs=0.0532,P＞0.05);血清VEGF及sFlt-1浓度与SLE疾病活动指数(SLEDAI)均呈正相关(rs=0.5046,P＜0.01,rs=0.5152,P＜0.01);血清VEGF浓度与肾组织活动指数(RAI)呈正相父(r=0.3386,P＜0.05),血清sFlt-1浓度与RAI无明显相关(rs=0.0240,P＞0.05);SLE患者中VEGF、sFlt-1水平与血压、血肌酐、尿素氮、C3、C4、C反应蛋白(CRP)无明显相关. 结论 血清VEGF及sFlt-1的水平可作为SLE病情活动评价指标,VEGF的高表达可能与增殖性肾小球病变相关,sFlt-1的表达与蛋白尿关系密切.     

血清血管内皮细胞生长因子的表达与狼疮性肾炎的关系

目的　探讨狼疮性肾炎 (LN)患者血管内皮细胞生长因子 (VEGF)在血清浓度与系统性红斑狼疮 (SLE)活动与肾脏病理等的关系。方法　采用ELISA法对 3 2例LN患者血清水平进行检测 ,并结合临床资料及肾脏病理进行相关分析。结果　LN患者血清VEGF水平较正常人升高 ,(P <0 .0 5 ) ,但各型LN组间血清VEGF浓度比较无明显区别 ;血清VEGF的浓度与SLE疾病活动指数 (SLEDAI)呈正相关 (P <0 .0 5 ) ;血清VEGF水平与尿蛋白无相关性 (r =0 .185 ,P >0 .0 5 )。结论　LN患者血清VEGF的水平升高 ,血清VEGF水平与肾脏病理类型 (Ⅱ、Ⅳ、Ⅴ型 )无相关性 ;血清VEGF水平可反映SLE的疾病活动程度 ;LN患者血清VEGF水平对尿蛋白的量无影响     

血清可溶性CD40配体和胎盘生长因子水平与冠状动脉粥样硬化病变的相关性

目的研究血清可溶性CIMO配体（sCD40L）和胎盘生长因子（PIGF）与冠状动脉粥样硬化病变的相关性。方法静脉采血检测健康对照组（30名）及冠心病组（60例）血清sCD40L及PIGF水平，并将冠心病组上述指标血清水平与该组患者冠脉造影病变支数及Gensini冠脉病变积分进行相关性分析。结果与对照组比较，冠心病组血清sCD40L与PIGF水平明显升高[（16．72±3．16）ng／L和（6．35±1．16）ng／L。（42．35±4．16）pg／ml和（15．8±2．73）pg／ml，P〈0．05]；血清sCD40L（r1=0．62，r2=0．67，r3=0．75，P〈0．05）与PIGF（r1=0．42，r2=0．53，r3=0．58，P〈0．05）水平与冠脉病变支数均呈正相关。结论血清sCIMOL与PIGF水平在冠心病患者中升高，可作为评估冠脉病变严重程度的指标。     

SLE患者血清催乳素水平检测及与SLEDAI积分的相关性

目的探讨催乳素在系统性红斑狼疮（SLE）发病中的作用。方法采用ELISA法检测64例SLE患者（SLE组）和20例查体健康者（对照组）血清催乳素水平,并评定SLE患者SLE疾病活动度指数（SLEDAI）积分,分析SLEDAI积分与血清催乳素水平的相关性。结果 SLE组血清催乳素水平明显高于对照组（P〈0.01）,SLE组SLEDAI积分为（11±6）分,其中≥10分（活动期）28例,〈10分（缓解期）36例。活动期血清催乳素水平明显高于缓解期（P〈0.001）;血清催乳素水平与SLEDAI积分呈正相关（r=0.490,P〈0.01）。结论催乳素在SLE发病中起重要作用;其水平变化有助于SLE的诊断和病情监测。     

血清聚集素水平与系统性红斑狼疮的相关性探讨

目的探讨血清聚集素在系统性红斑狼疮（SLE）发病中的作用。方法采用夹心ELISA法检测30例SLE患者（观察组）与30例正常患者（对照组）血清聚集素水平,对血清聚集素水平与疾病活动指数（SLEDAI）评分、血清补体C3和C4水平及临床特征进行相关性分析。结果观察组血清聚集素水平为（29．84±4．47）pg／ml,显著低于正常对照组的（44．47±4．58）pg／ml（t=12．524,P〈0．001）;血清聚集素水平与SLEDAI评分呈负相关（r=-0．805,P〈0．001）;与SLE补体C3、C4水平无相关性（r=0．263、0．272,P均〉0．05）,与脱发、面部红斑、口腔溃疡、关节炎、尿蛋白、自细胞减少、血小板减少等临床特征相关（t=2．922～4．600,P〈0．01）,与淋巴细胞减少无相关性（t=1．690,P〉0．05）。结论血清聚集素在SLE发生、发展中起重要作用。     

维生素D缺乏与系统性红斑狼疮的相关性研究

目的 探讨系统性红斑狼疮（SLE）患者维生素D缺乏现象与疾病活动性的相关性.方法 选取60例SLE患者及30例健康志愿者,收集研究对象临床资料;ELISA法检测血清25-羟基维生素D[25-（OH）D]水平;采用Pearson相关分析法分析血清25-（OH）D水平与SLE疾病活动指数（SLEDAI）、抗ds-DNA抗体滴度、补体C3、补体C4、尿蛋白定量、血清免疫球蛋白G（IgG）的相关性.结果 （1）SLE患者血清25-（OH）D水平[36.8（23.4,53.2）nmol/L]较健康志愿者[58.8（51.1,65.3） nmol/L]明显降低（P＜0.01）;（2）SLE患者中维生素D缺乏比例为53.3％,严重维生素D缺乏比例为15.0％,健康志愿者中维生素D缺乏比例为23.3％,严重维生素D缺乏比例为6.7％,两组比较差异具有统计学意义（P＜0.01）.（3）SLE患者血清25-（OH）D水平与SLEDAI（r=-0.35,P＜0.05）及抗ds-DNA抗体滴度（r=-0.42,P＜0.05）呈负相关,与补体C3（r=0.25,P＜0.05）、补体C4（r=0.28,P＜0.05）呈正相关,与尿蛋白定量、血清IgG水平无明显相关性（P＞0.05）.结论 SLE患者中维生素D缺乏现象普遍存在,血清维生素D水平与疾病活动性具有一定相关性.     

系统性红斑狼疮患者外周血细胞E-选择素的变化及相关性研究

目的通过测定系统性红斑狼疮（SLE）患者外周血细胞E-选择素水平，以了解E一选择素在SLE发病机制中的作用及临床意义。方法采用流式细胞仪检测31例SLE患者和20名健康对照者外周血细胞E-选择素水平。同时记录患者临床资料并作SLE病情活动性指数（SLEDAI）评分．检测血沉（ESR）、补体C3水平。分析E-选择素与SLE疾病活动的关系。结果31例SLE患者外周血E-选择素水平高于正常对照组（P〈0．01）。17例活动期与14例稳定期SLE患者E-选择素水平有显著区别（P〈0．01）。18例伴肾脏损害SLE患者外周血E-选择素水平与无肾脏损害患者差异无统计学意义（P〉0．05）。并且31例SLE患者外周血E-选择素水平与ESR、SLEDAI评分有显著正相关（r=0.687、r=0．693，P值均〈0．01），与血C3补体水平呈显著负相关（r=-0．512，P〈0．01）。结论E-选择素可能参与SLE发病，与病情活动性相关。     

女性系统性红斑狼疮患者血清腺垂体激素水平的变化及其与狼疮性肾炎的关系

目的研究女性系统性红斑狼疮（SLE）和狼疮性肾炎（LN）患者外周血腺垂体激素的水平变化及意义。方法采用化学发光法检测117例女性SLE患者及30例女性健康体检者血清泌乳素（PRL）和生长激素（GH）水平,同时采用放射免疫法测定抗ds-DNA抗体水平,并对其中的76例LN患者进行分析。结果女性SLE、LN患者的血清PRL和GH水平高于正常对照组,且活动期组高于静止期组（P均〈0.01）。SLE患者PRL、GH与抗ds-DNA抗体、SLEDAI评分均呈正相关,LN患者PRL、GH与抗ds-DNA抗体均呈正相关,SLE、LN患者血清PRL与GH水平均呈正相关。结论 PRL与GH可能相互作用,共同参与SLE、LN发病。     

食管鳞癌患者血清VEGF、Endostatin水平变化及意义

目的观察食管鳞癌患者血清血管内皮生长因子（VEGF）和内皮抑素（Endostatin）的水平变化,并探讨其意义。方法采用ELISA法检测126例食管鳞癌患者和14例健康对照者血清VEGF及Endostatin。结果食管鳞癌患者血清VEGF为（20.68±3.09）μg/L、Endostatin为（4.96±1.72）μg/L,健康对照者分别为（3.82±6.28）μg/L（、1.60±0.37）μg/L,两组相比,P均〈0.05。食管鳞癌患者血清中VEGF、Endostatin水平与肿瘤分化程度、TNM分期、肿瘤直径、淋巴结转移有关（P均〈0.01）,其血清VEGF与Endostatin的水平呈正相关（r=0.594,P〈0.01）。结论食管鳞癌患者血清VEGF、Endostatin水平升高,可作为食管鳞癌恶性程度及肿瘤负荷的预测指标。     

血清铁蛋白水平与成人系统性红斑狼疮疾病活动的关系

目的探讨成人系统性红斑狼疮(SLE)患者疾病活动度与血清铁蛋白(SF)的关系。方法初次确诊为SLE的患者40例依据SLE疾病活动指数(SLEDAI)评分分为稳定组与活动组。同期确诊为其他自身免疫性疾病的患者38例纳入其他对照组,40例健康体检者纳入正常对照组。电化学发光法检测SF水平,酶联免疫吸附(ELISA)法检测抗ds DNA抗体,同时回顾性收集SLE患者C反应蛋白(CRP)、红细胞沉降率(ESR)、补体及尿蛋白等实验室检查结果。结果 SLE患者SF水平高于其他对照组和正常对照组(P<0.05),且活动组SF水平高于稳定组(P=0.044)。SLE患者SF与SLEDAI评分(r=0.48,P<0.05)、抗ds DNA(r=0.34,P<0.05)、补体C3(r=-0.367,P=0.02)、C4(r=-0.371,P=0.018)均有相关性。另发现尿蛋白阳性的SLE患者SF水平较尿蛋白阴性者高(P<0.001)。结论 SF与SLE疾病活动密切相关,与SLEDAI评分、抗ds NDA抗体滴度及补体C3、C4等指标联合检测可判断成人SLE疾病活动程度,并指导临床治疗。     

Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma

Angiogenesis is a crucial process in the progression of multiple myeloma (MM). Vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) are multifunctional cytokines that potently stimulate angiogenesis including tumour neovascularization. Serum levels of VEGF and HGF were measured in 52 patients with MM by enzyme-linked immunosorbent assay (ELISA). Serum levels of VEGF and HGF were elevated in MM patients compared with healthy controls (VEGF: mean 0.31 ng/ml and 0.08 ng/ml respectively, P < 0.01; HGF: mean 2.17 ng/ml and 0.45 ng/ml, respectively, P < 0.001). In serial samples taken after chemotherapy, serum VEGF and HGF levels were correlated with M-protein levels. Serum levels of VEGF were higher in patients with extramedullary plasmacytomas than in patients without them (P < 0.05). They were also significantly higher in a group of patients who showed poor response to chemotherapy (P < 0.01). Serum levels of HGF were higher in patients with complications such as anaemia, hypercalcaemia and amyloidosis than in patients without these complications (P < 0.01, P < 0.05, P < 0.05 respectively). Both serum VEGF and HGF levels were significant predictors of mortality (P = 0.01, P = 0.02, respectively, log-rank test). The present study demonstrated that serum levels of VEGF and HGF are significantly elevated and dependent on the severity of MM, suggesting that measurement of VEGF and HGF may be useful for assessing disease progression and for predicting the response to chemotherapy in MM patients.     

结直肠癌患者血清中血管内皮生长因子和一氧化氮表达水平及其临床意义

目的:探讨结直肠癌患者血清中血管内皮生长因子(VEGF)和一氧化氮(NO)表达水平及其临床意义.方法:分别采用酶联免疫吸附测定(ELISA)法和分光光度法检测74例结直肠癌患者术前和45例结直肠腺瘤患者以及40例健康人血清中VEGF和NO的含量.结果:结直肠腺瘤患者血清VEGF和NO含量与健康人无明显差异(P＞0.05);结直肠癌患者血清VEGF和NO表达水平分别较结直肠腺瘤组以及健康人明显增高(P＜0.01),且结直肠癌浸润深度、有无淋巴结转移以及Dukes分期与血清VEGF和NO含量呈明显正相关(r=0.834,P＜0.01).结论:VEGF和NO与结直肠癌的发生发展密切相关,术前检测血清VEGF和NO含量可作为判断结直肠癌浸润转移以及Dukes分期的有效生物学指标.     

Serum levels of platelet-derived growth factor-BB and vascular endothelial growth factor as prognostic factors for patients with fulminant hepatic failure

Background and Aims: In animal models for acute liver injury, the administration of some angiogenic factors such as vascular endothelial growth factor (VEGF) and granulocyte‐colony stimulating factor (G‐CSF) are shown to reduce liver injury and improve liver proliferative capacity. The aim of the present study was to assess the role of angiogenic factors in fulminant hepatic failure (FHF). Methods: Serum levels of nine angiogenic factors (angiopoietin‐2, follistatin, G‐CSF, hepatocyte growth factor [HGF], interleukin‐8, leptin, platelet‐derived growth factor [PDGF]‐BB, platelet endothelial cell adhesion molecule‐1 and VEGF) were measured using the Bio‐Plex Protein Array System in 30 patients, 17 of whom were diagnosed with FHF, 13 with acute hepatitis (AH), and 20 controls. Results: Serum levels of PDGF‐BB and VEGF were lower in FHF patients than AH patients and controls (PDGF‐BB; 2050 ± 1572 pg/mL vs 4521 ± 2419 pg/mL vs 8506 ± 5500 pg/mL, VEGF; 39 ± 38 pg/mL vs 144 ± 122 pg/mL vs 205 ± 121 pg/mL). By using univariate logistic regression models, serum levels of PDGF‐BB and VEGF were associated with poor outcomes. Serum PDGF‐BB levels were strongly correlated with serum VEGF levels (r = 0.70). Furthermore, serum PDGF‐BB levels were significantly correlated with platelet counts (r = 0.79), PT activity (r = 0.37) and D.Bil/T.Bil ratio (r = 0.50), while serum VEGF levels were significantly correlated with platelet counts (r = 0.68) and PT activity (r = 0.38). Conclusions: We consider that serum levels of PDGF‐BB and VEGF are worth investigating as biomarkers for predicting outcomes of FHF patients.     

冠状动脉介入治疗对冠心病患者血管内皮生长因子水平的影响及意义

目的:检测冠心病(CHD)患者介入治疗前后血管内皮生长因子(VEGF)的动态变化并探讨其临床意义。方法:150例CHD患者分别于介入治疗前,术后即刻,术后6、12、24、48h检测VEGF的动态变化,同时记录血流动力学指标及不良事件发生情况。结果:CHD患者血管VEGF水平明显升高(P<0·01),其中完全血运重建组(A亚组)术后6h VEGF水平降至正常;部分血运重建组(B亚组)术后48hVEGF水平仍高于正常(P<0·01),但明显低于术前(P<0·05);急性闭塞组(C亚组)VEGF水平急剧升高,显著高于治疗前(P<0·01)。结论:监测血VEGF水平可作为了解冠状动脉介入治疗效果的良好指标。     

非霍奇金淋巴瘤患者sVEGF和sbFGF水平的变化及临床意义

目的:研究非霍奇金淋巴瘤(NHL)患者血清血管内皮生长因子(sVEGF)及血清碱性成纤维细胞生长因子(sbFGF)水平与临床特征的关系,探索其临床意义.方法:ELISA法检测36例不同病期NHL患者sVEGF、sbFGF水平,并收集临床资料,进行统计分析.结果:NHL患者sVEGF、sbFGF水平明显高于对照组(均P＜...     

No association between serum levels of insulin-like growth factor-I, vascular endothelial growth factor, prolactin and clinicopathological characteristics of breast carcinoma after surgery

BACKGROUND: Angiogenesis is essential for tumour growth and metastasis. Vascular endothelial growth factor (VEGF) has been suggested as the major angio-genic factor in breast carcinoma. Both insulin-like growth factor-I (IGF-I) and prolactin are involved in the progression of breast cancer at least partly by stimulating angiogenesis. AIM: The aim of the present study was to investigate the association between serum IGF-I, VEGF and prolactin levels and clinicopathological characteristics of breast carcinoma. METHODS: Serum IGF-I, VEGF and prolactin levels were measured in breast cancer patients and controls and these levels were compared with well-known clinicopathological characteristics of breast carcinoma, including tumour size, axillary lymph node and oestrogen/progesterone receptor status, tumour grade and disease stage. RESULTS: Serum prolactin, VEGF and IGF-I levels were found to be similar in breast cancer patients and control subjects (P > 0.05). When the patients were divided into groups according to their tumour size, axillary lymph node status, tumour grade, oestrogen/progesterone receptor status and disease stage, no significant differences in serum prolactin, VEGF and IGF-I levels were found among the groups (P > 0.05). CONCLUSIONS: The present study failed to demonstrate an association between serum levels of VEGF, IGF-I and prolactin and well-known clinicopathological characteristics of breast carcinoma.     

非小细胞肺癌患者血清血管内皮生长因子、血小板衍生生长因子和表皮生长因子受体测定的临床意义

目的 探讨血清血管内皮生长因子(vascular endothelial growth factor,VEGF)、血小板衍生生长因子(platelet-derived growth factor,PDGF)和表皮生长因子受体(epidermal growth factor receptor,EGFR)测定在非小细胞肺癌(non-small cell lung cancer,NSCLC)诊断和预后判定中的意义.方法 采用双抗体夹心ABC-ELISA法测定31例NSCLC患者及30名健康者血清VEGF、PDGF和EGFR的含量.结果 NSCLC患者血清VEGF、PDGF和EGFR测定值均高于健康对照组(P值均＜0.01).血清VEGF、PDGF和EGFR测定值与NSCLC病理分型无关(P值均＞0.05),与远处转移有关,远处转移组的测定值高于未转移组(P＜0.05～0.01).NSCLC患者血清VEGF与PDGF测定值之间呈显著正相关(r=0.641,P＜0.01),血清VEGF和EGFR测定值呈正相关(r=0.369,P＜0.05).结论 检测血清VEGF、PDGF和EGFR水平对NSCLC的诊断和预后判定具有一定价值.     

大肠癌患者血清中血管内皮生长因子和一氧化氮的检测及其临床意义

目的　研究大肠癌患者血清中血管内皮生长因子 (VEGF)和一氧化氮 (NO)表达水平 ,探讨其在大肠癌中的临床意义。方法　分别采用酶联免疫吸附测定 (ELISA )法和分光光度法检测 5 9例大肠癌患者术前血清中VEGF和NO水平 ,并与 3 0例健康人对照。结果　大肠癌患者血清VEGF和NO表达水平均较健康人明显增高 (P <0 .0 1) ,且随着大肠癌浸润深度增加、有淋巴结转移以及Dukes分期愈晚者而显著增高 (P <0 .0 1)。血清VEGF与NO含量呈明显正相关 (r =0 .817,P <0 .0 1)。结论　VEGF和NO与大肠癌浸润和转移有关 ,术前检测VEGF和NO表达水平有可能作为反映大肠癌恶性进程的重要参考指标     

结直肠癌患者血清中血管内皮生长因子的水平及其意义

目的:测定结直肠癌患者血清血管内皮生长因子(VEGF)的含量,分析其与临床病理指标间的关系。方法:采用ELISA法测定42例初治结直肠癌患者血清VEGF含量,正常对照30例。结果:结直肠癌患者血清VEGF浓度为274.21±218.38 pg/ml,明显高于正常对照组浓度(169.06±68.01 pg/ml,P<0.02),结肠癌患者血清VEGF浓度为346.52±168.57 pg/ml明显高于直肠癌患者(237.31±124.10 pg/ml,P<0.05)。Dukes B、C、D期组患者血清VEGF浓度与对照组相比均有明显差异(P<0.05),Dukes D期组与Dukes A、B、C期组亦均有明显差异(P<0.05)。结直肠癌患者血清VEGF浓度与年龄、性别无相关性(P>0.05)。结论:VEGF与结直肠癌的发生发展及癌肿部位有关,对探讨结直肠癌的发生机制,病情判断,预后及指导治疗有一定价值,对早期诊断似无帮助。